- The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression versus placebo
- There are currently very limited treatment options for SPMS, a form of MS associated with gradual worsening of symptoms and accumulation of disability, independent of relapses
- EXPAND is the largest study ever conducted in SPMS, and is part of Novartis' ongoing leadership and commitment to people with MS
Catalyst
Slingshot members are tracking this event:
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 25, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Baf312, Efficacy, Secondary Progressive Multiple Sclerosis
